Immune response to GeneVac-BⓇ (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso

•GeneVac-B® showed an excellent immune response.•Its low cost makes it a good tool to prevent hepatitis B infection.•Post-vaccination evaluation should be considered in persons with comorbidities. This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with th...

Full description

Saved in:
Bibliographic Details
Published in:IJID regions 2024-12, Vol.13, p.100483, Article 100483
Main Authors: Ouattara, Nina Genéviève Mathuola, Sanou, Armel Moumouni, Napon-Zongo, Delphine, Coulibaly, Abou, Korogho, Sylviane, Dera, Abdoulaye, Nikièma, Achille S., Kyelem, Eric, Gansoré, Nawatou, Ilboudo, Abdoul Kader, Diendéré, Jeoffray, Ouédraogo, Gautier Henri
Format: Article
Language:English
Subjects:
Burkina Faso
GeneVac-B
Hepatitis B
Immune response
Nonresponse factors
Original Report
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•GeneVac-B® showed an excellent immune response.•Its low cost makes it a good tool to prevent hepatitis B infection.•Post-vaccination evaluation should be considered in persons with comorbidities. This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with the GeneVac-BⓇ vaccine in Burkina Faso under actual conditions of use. This cross-sectional study included individuals fully vaccinated with GeneVac-BⓇ. For each consenting participant, sociodemographic and clinical data were collected using a structured questionnaire. Approximately 4 ml of whole blood was collected for immunological (anti-HBs, hepatitis B surface antigen, anti-hepatitis C virus, and anti-HIV) and biochemical (blood glucose, total cholesterol, and triglycerides) testing. The anti-HBs titer was used to determine the immune response. A total of 392 participants were included in the study. The mean age was 35.5 ± 15.3 years. Approximately 56% had been previously exposed to hepatitis B virus. Overall, 380 participants had an anti-HBs titer ≥ 12 mIU/ml indicating a seroprotection rate of 96.9%, and 12 had a titer 240 mg/dl), and 8 (8/12; 66.7%) were older than 40 years of age. The results showed an excellent immune response to GeneVac-BⓇ in our study population. However, age > 40 and high total cholesterol appear to be factors associated with nonresponse.
ISSN:2772-7076
2772-7076
DOI:10.1016/j.ijregi.2024.100483